Is HRT safe, and safe for whom

What the FDA changed, and when

Two dates, and collapsing them is the most common error on this subject. The FDA announced in November 2025 that it would remove the boxed warnings for cardiovascular disease, breast cancer and probable dementia from systemic menopause hormone therapy. It approved the labeling changes in February 2026. Announced and approved are different events three months apart, and approved is still not the same as printed.

Manufacturers republish their labels on their own schedules, so the rollout is visible in the structured data. On 2026-08-15 we counted boxed warning sections in the DailyMed SPL XML for 8 menopause hormone products, one per row below. 2 had dropped the warning and 6 still carried it, and 2 of the labels still carrying it were posted after the February 2026 approval date.

Method: sections carrying LOINC code 34066-1, the SPL code for a boxed warning section, counted in each label's structured XML. The rows that still carry one are the control that shows the count detects the section where it exists, so an absence is a finding rather than a failed read. Re-run before restating any of it. What the change actually means for you.

What the WHI showed, and who it showed it about

The Women's Health Initiative stopped its estrogen-plus-progestin arm in 2002 because invasive breast cancer crossed the stopping boundary. The hazard ratio was 1.26. In absolute terms, over a mean 5.2 years, the trial reported 8 more invasive breast cancers, 8 more strokes, 8 more pulmonary emboli and 7 more coronary events per 10,000 person-years, against 6 fewer colorectal cancers and 5 fewer hip fractures. Those are the numbers behind the headline, and they are smaller than the headline sounds.

The part the shorthand drops is who was in the room. Participants averaged 63.4 years at enrollment, and most were more than a decade past menopause. When the same data was re-analyzed by time since menopause in 2007, the coronary heart disease signal separated by group: an absolute excess of minus 6 events per 10,000 person-years for women within 10 years of menopause, 4 for women 10 to 19 years out, and 17 for women 20 or more years out. Stroke rose in every group, which is why the honest version of this is stratified rather than reassuring.

And the trial that produced the breast cancer headline used conjugated equine estrogens with medroxyprogesterone acetate. The parallel WHI trial of estrogen alone, in women who had had a hysterectomy, found breast cancer incidence going the other way: 238 cases against 296 on placebo after more than 20 years, hazard ratio 0.78, with lower breast cancer mortality too. The full stratified answer, with all the absolute numbers.

Route is a safety decision, not a preference

Estradiol swallowed as a pill passes through the liver before it reaches general circulation. Estradiol absorbed through the skin does not. That difference in first-pass hepatic metabolism is the mechanism behind the observed difference in venous thromboembolism risk between oral and transdermal estrogen reported in the BMJ 2019 nested case-control study: oral therapy at an adjusted odds ratio of 1.58 against no exposure, transdermal preparations at 0.93 with a confidence interval crossing 1. The same study put conjugated equine estrogen with medroxyprogesterone acetate highest at 2.10, and estradiol lower than conjugated equine estrogen within both preparation types.

A shopper reading a price table cannot see any of that, which is the reason the estradiol page prices every form side by side and then says not to pick on price alone. Across the 13women's-wing platforms we verify, the cheapest published route and the lowest-risk route are not the same route.

Every safety page on this site

No provider pays for placement in any of these. Where a rate exists on an FDA label we publish it with the label's own placebo column; where no rate exists we say so instead of estimating one.

Report a side effect, and check who is prescribing

Adverse reactions to a prescription hormone can be reported directly to FDA MedWatch as well as to your prescriber. Reports from patients are what populates the postmarketing sections of the labels quoted across these pages.

Who writes the prescription changes what you get told before you buy, which is what our Transparency Grade measures across the 16 platforms on the roster. How the grade is built, and the wing-level rankings for menopause HRT and men's TRT.

Sources

• FDA, HHS advances women's health and removes misleading FDA warnings from hormone replacement therapy (November 2025 announcement)
• FDA, approved labeling changes for menopausal hormone therapy products (February 2026 approval)
• The Menopause Society, 2022 hormone therapy position statement (PMID 35797481)
• Writing Group for the WHI Investigators, risks and benefits of estrogen plus progestin, JAMA 2002 (PMID 12117397)
• Rossouw et al, postmenopausal hormone therapy and cardiovascular disease by age and years since menopause, JAMA 2007 (PMID 17405972)
• Chlebowski et al, menopausal hormone therapy and breast cancer incidence and mortality, JAMA 2020 (PMID 32721007)
• Vinogradova et al, HRT and risk of venous thromboembolism, BMJ 2019 (PMID 30626577)
• DailyMed structured product labels for all 8 products in the boxed-warning table above, each linked from its own row, read 2026-08-15.

This is general information, not medical advice. Hormone therapy is a prescription treatment and whether it is right for you, at which dose and by which route, is a decision for you and a licensed clinician. Written and reviewed by Iacob Pastina.